Trexquant Investment LP Reduces Stock Holdings in Aligos Therapeutics, Inc. $ALGS

Trexquant Investment LP decreased its position in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 44.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,254 shares of the company’s stock after selling 30,796 shares during the period. Trexquant Investment LP owned about 0.63% of Aligos Therapeutics worth $316,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALGS. Tower Research Capital LLC TRC raised its holdings in Aligos Therapeutics by 2,073.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after acquiring an additional 622 shares during the period. Northern Trust Corp bought a new stake in Aligos Therapeutics during the 4th quarter valued at $205,000. Golden State Wealth Management LLC raised its holdings in Aligos Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company’s stock valued at $44,000 after acquiring an additional 2,674 shares during the period. Readystate Asset Management LP purchased a new position in Aligos Therapeutics during the 1st quarter valued at about $375,000. Finally, AlphaQuest LLC purchased a new position in Aligos Therapeutics during the 1st quarter valued at about $130,000. Institutional investors own 60.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright started coverage on Aligos Therapeutics in a report on Monday, August 18th. They set a “buy” rating and a $50.00 target price for the company. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Aligos Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $50.00.

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock opened at $11.22 on Wednesday. The stock has a market cap of $69.00 million, a P/E ratio of -0.57 and a beta of 2.79. Aligos Therapeutics, Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $46.80. The firm’s fifty day moving average price is $8.96 and its 200-day moving average price is $8.20.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share for the quarter, topping the consensus estimate of ($2.35) by $0.82. The firm had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $0.43 million. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%. Sell-side analysts predict that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).